



THE
BLADDER CANCER
COMPANY

Photocure ASA - Share option grant

Oslo, Norway, 23 December - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

A total of 633,500 share options, equal to 2.3% of total shares issued in the Company, were granted to employees at an exercise price at NOK 59.57. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.

The options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior executives (the "Guidelines"), as approved by Photocure's annual general meeting held 23 May 2024. The share option program and properties of the options are further described in the Guidelines.

Of the total grant the following was granted to primary insiders:

- Dan Schneider, President and Chief Executive Officer, 125,000 options.
- Erik Dahl, Chief Financial Officer, 65,000 options.
- Geoffrey Coy, Vice President and General Manager North America, 50,000 options.
- Anders Neijber, Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D, 50,000 options.
- Anja Gossens-von der Heidt, Head of Global Human Resources, 40,000 options.
- David Moskowitz, Head of Investor Relations, 20,000 options

Further, the Company has issued customary annual stock options to the members of the board of directors in accordance with the resolution made under section 5 of the annual general meeting held 23 May 2024. Chairperson, Dylan Hallerberg, was issued 9,979 stock options, and the other members of the board, Neal Shore and Ghizlane Tagmouti were issued 5,124 options each. The strike price was set at a 10% premium to the weighted average closing price in the 30 trading days following the annual general meeting on 23 May 2024, which corresponds to a strike price of NOK 69.36 per share.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached.

For further information, please contact:

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and

listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com and www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.